LYL1, a member of the class II basic helix-loop-helix transcription factors, is aberrantly expressed in a fraction of human T-cell acute lymphoblastic leukemia. Here, we generated transgenic mice ubiquitously overexpressing LYL1 using a construct expressing full-length cDNA driven by a human elongation factor 1a promoter. Four independent lines exhibiting high LYL1 expression were established. Of these transgenic mice, 96% displayed loss of hair with a short kinked tail. Furthermore, 30% of them developed malignant lymphoma, with an average latent period of 352 days. In these mice, histological examination revealed tumor cell infiltration in multiple organs and immunohistochemical analysis showed that the infiltrated tumor cells were either CD3 or CD45R/B220-positive; fluorescence-activated cell sorter analysis indicated that each tumor consisted either of mainly CD4, CD8 double-positive T cells or mature B cells; the clonality of LYL1-induced lymphoma was confirmed by T-cell receptor rearrangement and immunoglobulin heavychain gene rearrangement analyses. Mammalian twohybrid analysis and luciferase assay suggested that excess LYL1 blocked the dimerization of E2A and thus inhibited the regulatory activity of E2A on the CD4 promoter. Reverse transcription-polymerase chain reaction results showed that the expression of certain E2A/HEB target genes was downregulated. Taken together, our results provide direct evidence that aberrant expression of LYL1 plays a role in lymphomagenesis.
Introduction
The basic helix-loop-helix (bHLH) transcription factor family plays an important role in a variety of developmental processes, including hematopoiesis, neurogenesis, myogenesis, cardiogenesis and pancreatic development (Hjalt, 2004) . Proteins of this family share a homologous bHLH motif, which is responsible for proteinprotein as well as protein-DNA interactions (Jones, 2004) . The bHLH transcription factor proteins are divided into two major groups (Murre et al., 1994) . Class I bHLH proteins, including E2A (E47 and E12) and HEB, are expressed in various tissues and are capable of forming either homo-or heterodimers. Class II bHLH proteins, such as myogenin and MyoD, are expressed in a tissue-specific manner. Unlike Class I proteins, Class II proteins do not form homodimers. Instead, they only form heterodimers with Class I proteins. Class II bHLH proteins can bind to E-box elements only when they form heterodimers with Class I proteins. To date, 242 bHLH proteins have been identified and divided into seven groups according to their expression patterns, dimerization capabilities and DNA-binding specificities (Massari and Murre, 2000) .
LYL1 gene belongs to the Class II bHLH transcription factor family. It was first identified at chromosomal translocation loci [t (7; 19) (q35; p13)] from a human T-cell leukemia cell line, and ectopic expression of LYL1 has been observed in a fraction of human T-cell acute lymphoblastic leukemia (ALL) (Mellentin et al., 1989; Ferrando et al., 2002; Ferrando and Look, 2003) . The expression of the LYL1 gene is restricted to hematopoietic cells, including myelocytes, erythrocytes and B lymphocytes in adults (Visvader et al., 1991; Kuo et al., 1991) , but the biological function of LYL1 remains largely unknown. TAL1 (also known as SCL) and TAL2 belong to the Class II bHLH protein family as well and share a 90% sequence identity with LYL1 in their bHLH motif (Baer, 1993) . Similar to LYL1, sustained expression of TAL1/2 owing to chromosomal translocation is associated with a T-cell leukemia/lymphoma (Xia et al., 1991; Begley and Green, 1999) . Both LYL1 and TAL1/2 proteins can interact with Class I bHLH proteins (Hsu et al., 1994; Xia et al., 1994; Miyamoto et al., 1996) and LIM-domain-only (LMO) proteins through their bHLH motifs.
Although the expression pattern of LYL1 overlaps with that of SCL/TAL1 (Jane Visvader et al., 1991; Kuo et al., 1991) , LYL1 did not compensate for embryonic lethality owing to the absence of yolk sac hematopoiesis in SCL/TAL1 knockout mice (Robb et al., 1995; Shivdasani et al., 1995) , which indicated that LYL1 might play a different role from that of SCL/TAL1, at least in early hematopoiesis.
To date, the oncogenicity of LYL1 has not been directly demonstrated. In the present study, we produced transgenic mice ubiquitously overexpressing LYL1 with a construct in which the human elongation factor 1a (EF-1a) promoter drove the expression of LYL1 full-length cDNA. Transgenic mice developed lymphoma and the possible carcinogenic mechanisms were further studied.
Results

LYL1 transgenic mice
To generate LYL1 transgenic mice, full-length mouse LYL1 cDNA was used. The LYL1-construct ( Figure 1a ) was injected into mice pronuclei and 13 founder mice were established. Exogenous LYL1 genes were detected by Southern blot analysis (Figure 1b) , and LYL1 expression was confirmed in transgenic mice with reverse transcription-polymerase chain reaction (RTÀPCR), Northern blot and western blot analyses. Expression of the transgene was detected in the thymus (Figure 1c and d) , liver, spleen and kidney (data not shown). Four independent lines of transgenic mice (26, 29, 38 and 83) showing relatively high LYL1 expression in the thymus were selected for further study.
The four selected founders and 96% (115/120) of their LYL1-positive progeny exhibited short kinked tails after birth (Figure 2a ). These mice also exhibited a loss of hair in major regions of the body, including the back and periorbital area. Hair loss was temporary but occurred repeatedly throughout the lifetime of the mice. The abnormalities in the development of tail and hair occurred concurrently. LYL1-homozygous mice, developed by crossing two transgenic mice, showed shorter and curlier tails than LYL1-heterozygous mice. In addition, homozygotes revealed a severe loss of hair and half (5/10) of them died immediately after birth. The rest of homozygotes died within 3 months without developing malignant tumors. Histological structures of major organs including brain, heart, lung, kidney and liver showed no obvious abnormality in these mice (data not shown). Similar phenomena, including embryonic lethality and abnormality in tail and hair, have also been observed in SCL/TAL1 transgenic mice (Aplan et al., 1997) . Taken together, these data indicated that, similar to SCL/TAL1, aberrant expression of LYL1 disturbed normal development of the tail and hair follicles and could be lethal when expressed at high levels.
Overexpression of LYL1 induces malignant lymphoma
Forty transgenic mice (heterozygotes) were generated by crossing founder mice with C57BL/6 wild-type mice and were followed to observe their long-term fate. Forty non-transgenic littermates and 40 C57BL/6 mice were used as controls. Thirty percent (12/40) of the transgenic mice developed lymphoma, with an average latent period of 352 days. The shortest latency observed was 207 days after birth ( Figure 2b and Table 1 ). In contrast, none of the control mice developed lymphoma after 20 months. Among those mice that developed lymphoma, four showed thymus enlargement accompanied by splenomegaly, hepatomegaly and lymph node enlargement (Table 1) . Atypical lymphocytes with enlarged nuclei infiltrated and destroyed the normal structures of the thymus, spleen, liver and lymph nodes. Tumor cell infiltration was also observed in the kidney and lung (Figure 2c ). The other eight mice that developed tumor showed a lack of thymus enlargement but showed spleen, liver and lymph node enlargement as well as widespread tumor infiltration (Table 1 and data not shown). These observations indicated that ectopic overexpression of LYL1 is oncogenic and LYL1-induced lymphoma is highly malignant, with the infiltration of multiple organs.
Characterization of lymphoma cells in LYL1-transgenic mice To characterize tumor cells derived from LYL1 transgenic mice, cells from the thymus and spleen were and CD8 but negative for B220, a pan B-cell marker, indicating a diagnosis of T-cell originated lymphoma ( Figure 3a ). For those mice without thymus enlargement, tumor cells derived from the spleen were positive for B220 but not for BP1, a marker expressed on early B-lymphocytes, indicating a diagnosis of mature B-cell lymphoma. In either case, T-and B-cell populations showed no significant difference from those in wild-type mice with these antibodies (Table 2) . To further confirm the monoclonality of the tumor, analyses on TCR-b gene rearrangement and immunoglobulin heavy-chain (IgH) gene rearrangement were performed. Clonal T-cell expansion was observed only in mice with an enlarged thymus (#26 and #83; Figure 3b and Table 2 ), whereas the expansion of clonal B cells was detected in spleens of mice without thymus enlargement (#2649, #26418, #26742, #291, #292, #381, #3816 and #83119; Figure 3c and Table 2 ). (Figure 3d ). These results demonstrated that ectopic overexpression of LYL1 facilitated the development of a lymphoma, the tumor cells of which were mainly CD4, CD8 double-positive T-lymphocytes or mature B-lymphocytes.
LYL1 blocks formation of E2A/HEB heterodimer and E2A/E2A homodimer E2A, a transcription regulatory factor, plays a crucial role in normal lymphocytic development. The activity of E2A requires the formation of a homo-or heterodimer in different cell lineages. In T-lymphocytes, E2A interacts with HEB, a member of the Class I bHLH family and activates target genes, whereas in Blymphocytes, E2A functions through the formation of a homodimer to regulate downstream genes (Lazorchak et al., 2005; Murre, 2005) . As LYL1 can also interact with E2A (Hsu et al., 1994; Xia et al., 1994; Miyamoto et al., 1996) , we asked whether ectopic overexpression of LYL1 had any effect on E2A dimerization. By using a mammalian two-hybrid system, we found that LYL1 interacted with E2A although this interaction was weaker than that of E2A-HEB ( Figure 4a ). When E2A, HEB and LYL1 were co-expressed, the formation of the E2A/HEB heterodimer was blocked by LYL1 in a dose-dependent manner ( Figure 4a ). The formation of the E2A homodimer was also suppressed by LYL1 (Figure 4b ). To further examine whether LYL1 did form heterodimer with E2A in vivo, we performed immunoprecipitation and detected LYL1/E2A heterodimer in the thymuses of two T-cell lymphoma-developed mice ( Figure 4c ). These results suggested that LYL1 affects the normal function of E2A by competitively blocking the formation of the E2A/E2A homodimer or the E2A/ HEB heterodimer.
LYL1 inhibits regulatory function of E2A/HEB heterodimer E2A regulates the expression of target genes through binding to an E-box consensus sequence. In T-lymphocytes, CD4 transcription is activated by E2A, which forms a complex with HEB and binds to the E-box element of the CD4 enhancer (Sawada and Littman, 1993) . In the present study, we used a luciferase reporter cassette driven by the CD4 enhancer-promoter to test the effect of LYL1 on the transcription-activating capacity of E2A ( Figure 5a ). Luciferase cassette was activated even without exogenous E2A expression, reflecting endogenous E2A/HEB expression. Co-transfection with E2A expression vector promoted this activity. Further upregulation of luciferase activity was observed in the presence of both E2A and HEB. The activation effect of E2A was significantly decreased when HEB was substituted by LYL1. Decreased luciferase activity was also observed when E2A, HEB and LYL1 were concurrently expressed. This is consistent with the result that LYL1 interfere the E2A-HEB interaction ( Figure 4a ). Similar results were obtained LYL1 overexpression causes T-and B-cell lymphoma Y Zhong et al when E2A was co-transfected with SCL/TAL1 (Figure 5a ). To see whether LYL1 affected the regulatory activity of E2A/HEB in vivo, some of the E2A/HEB target genes were studied by RTÀPCR (Figure 5b ). The expression of CD5, pTa and RAG1/2 (O' Neil et al., 2004) in the thymus of T-cell lymphomadeveloped mice was downregulated, indicating that the E2A function was disturbed in these mice. Our data LYL1 overexpression causes T-and B-cell lymphoma Y Zhong et al suggested that LYL1 suppressed the activating effect of E2A by inhibiting E2A-HEB dimerization.
Discussion
We generated LYL1 transgenic mice in which LYL1 cDNA was under the control of a ubiquitous promoter (EF-1a). Ninety-six percent of these mice displayed short, kinked tails and alopecia. It was reported that the manipulation of certain genes causes tail abnormalities in mice. One of the best-known examples is the Brachyury (T) gene, which encodes a T-box transcription factor. T-gene-mutant heterozygous mice exhibit short tails, and the homozygous mutant mice are embryonic lethal (Wilson and Conlon, 2002) . Another example is the Pax1 knockout mice, in which an apparent kinked tail is observed only in the Pax1 null homozygotes (Wilm et al., 1998) . It is possible that the observed tail abnormality was induced by the insertion of the LYL1 transgene into the genomic loci of a certain crucial gene. However, in the four different founder lines displaying a similar phenotype, the LYL1 construct did not integrate into any known gene (data not shown). In addition, tail abnormalities and hair loss occurred concurrently in individual mice. Of note, similar phenotypes have also been observed in SCL/TAL1 transgenic mice, in which SCL/TAL1 cDNA was driven by a ubiquitous regulatory element (Aplan et al., 1997) . Thus, the observed phenotypes were due to the ectopic expression of LYL1 rather than by disrupting other genes. Using these transgenic mice, we provided the first direct evidence that LYL1 is lymphomagenic. High LYL1 expression was lethal as half of the homozygous mice died at birth and the rest died within 3 months. Although the LYL1 gene was initially identified from a T-ALL and thought to be a T-cell-associated oncogene, both T-and B-cell lymphoma were observed in our LYL1 transgenic mice. Our observation demonstrates that the oncogenicity of LYL1 is not limited to the Tlymphocyte lineage. Supporting this view, Meng et al. (2005) recently reported that LYL1 is highly expressed in the majority of cases of acute myeloblastic leukemia (AML) and myelodysplastic syndrome (MDS), indicating that overexpression of LYL1 might be involved in the development of AML and MDS. In addition, breast and liver tumors were also observed in LYL1 transgenic mice, although with a low incidence (Y Zhong, S Toyokuni and Y Yamada, unpublished data). Although the aberrant expression of LYL1 is responsible for the oncogenicity of LYL1, this protein did not determine the target cell for carcinogenesis. We observed no apparent differences in LYL1 RNA levels in the spleen and thymus among pre-lymphoma stage, B-and T-cell lymphoma mice (Figure 5b and data not shown). Mice derived from a founder line, of which exogenous LYL1 was inserted into supposedly gene-poor genomic areas, developed both T-and B-cell lymphoma, indicating that T-or B-cell lymphomagenesis in LYL1 mice is independent of the integration site. Further study would greatly facilitate our understanding of LYL1-mediated oncogenesis.
We further investigated the effect of LYL1 on the function of E2A in vitro and found that LYL1 disrupts the normal function of E2A by competitively binding with E2A. This finding is consistent with the observation that E2A-deficient mice developed T-cell lymphoma with a relatively high frequency (Bain et al., 1997; Yan et al., 1997) . LYL1 only partially inhibits E2A function, so that the residual E2A activity may be responsible for the low incidence of LYL1-induced lymphoma. However, the disturbance of E2A by LYL1 does not fully explain the LYL1-mediated oncogenic effect that also involves B-cell lineage. It was reported that nuclear factor-kB (NF-kB) dysfunction is associated with some 
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T-cell neoplasms (Gilmore et al., 1996; Dolcet et al., 2005) . In Jurkat cells, LYL1 interacts with NF-kB1 p105, a precursor of NF-kB, and inhibits NF-kBdependent transcription by reducing NF-kB activity (Ferrier et al., 1999) . NF-kB1 p105 might be involved in the development of T-cell lymphoma. LYL1 functions through its bHLH domain, which shares a 90% sequence identity with the bHLH domain of the SCL/TAL1 and TAL2 gene (Baer, 1993 ). An increasing number of evidence suggested that SCL/ TAL1 and LMO1/2 contributes to the inhibition of E2A-HEB and therefore SCL/TAL1-induced leukemogenesis (Condorelli et al., 1996; Larson et al., 1996; Aplan et al., 1997; Chervinsky et al., 1999) . By using tal1/scl/E2A þ /À and tal1/scl/HEB þ /À mice, O'Neil et al. (2004) demonstrated that SCL/TAL1 repressed E2A/ HEB by the recruitment of the mSin3A/HDAC complex Figure 4 Effect of LYL1 on dimerization of E2A. Mammalian two-hybrid assay was used to study the effect of LYL1 on the formation of (a) E2A/HEB heterodimer and (b) E2A/E2A homodimer. Expression vectors in various combinations were cotransfected into 293T cells. Forty-eight hours later, CAT ELISA assay was performed as described in Materials and methods. Filled triangle indicates gradually increased doses of competitor (pEF-BOS-LYL1) that were 5-, 10-and 20-fold of that of pGBD-E2A, respectively. Protein interactions were indicated by CAT enzyme activity. Each co-transfection experiment was repeated in triplicate (refer to Materials and methods for details. # Po0.05 vs co-transfected with GBD-E2A and VAD-HEB; *Po0.001 vs co-transfected with GBD-E2A and VAD-E2A). (c) Co-immunoprecipitation of LYL1 and E2A. Proteins extracted from thymus of wild type (Wt), pre-lymphoma stage (#265 and #296) and T-cell lymphomadeveloped mice (#83 and #2644) were immunoprecipitated with antibody against LYL1 and detected by western blotting with antibody against E47. IP, immunoprecipitation; WB, western blot; H, heavy chain. Figure 5 LYL1 inhibits the regulatory activity of E2A/HEB (a) Effect of E2A/HEB on CD4 enhancer-promoter. A firefly luciferase reporter vector driven by a CD4 enhancer-promoter (CD4 enh-pro) was transfected into 293T cells with vectors expressing LYL1, E2A, SCL/TAL1 or HEB in various combinations. CD4 enhancer and promoter activities are presented as a ratio of firefly luciferase activity to sea pansy luciferase activity. GL3-Basic is a promoterless vector, which was used as a negative control for background. The transfection experiment was performed in triplicate. ( # Po0.05 vs transfected with promoter construct alone; *Po0.05 vs cotransfected with E2A and HEB). (b) Expression of the E2A/HEB target genes. RTÀPCR was performed using RNA extracted from the thymus of wild type (Wt), prelymphoma-stage and T-cell lymphoma mice. RTÀPCR, reverse transcription-polymerase chain reaction.
LYL1 overexpression causes T-and B-cell lymphoma Y Zhong et al to its target genes. Like SCL/TAL1, LYL1 inhibited the regulatory activity of E2A/HEB, and some of the E2A/ HEB target genes, including CD5, pTa and RAG1/2, were downregulated in the thymus of lymphomagenic LYL1 mice (Figure 5b ). LYL1 significantly repressed CD4 transcriptional activity either in the presence or absence of exogenous E2A/HEB (Figure 5a ), suggesting that LYL1 has mechanisms other than simple competitive binding to E2A/HEB heterodimers or E2A homodimer. The involvement of other factors that cooperate with LYL1 might explain the relatively low incidence of LYL1-mediated oncogenesis observed in our study.
In conclusion, we demonstrated that aberrant expression of LYL1 plays a role in lymphomagenesis. The molecular mechanism of LYL1-induced lymphomagenesis remains to be elucidated and detailed identification of LYL1-target genes is warranted for further understanding of the oncogenic effect of LYL1.
Materials and methods
Plasmid constructs
Mouse LYL1 (GenBank NM_008535; 556-1392) and E47, a major product of the E2A gene, (GenBank AF352579; 87-2033) cDNA were amplified from spleen by RTÀPCR; human SCL/TAL1 cDNA (GenBank NM_003189; 578-1573) was amplified from liver. A human HEB cDNA (GenBank NM_003205; 295-2343) clone was kindly provided by Dr Robert E Kingston (Department of Genetics, Massachusetts General Hospital, Boston, MA, USA). Amplified fragments were cloned into the XbaI site of the pEF-BOS expression vector (Mizushima and Nagata, 1990 ) yielding pEF-BOS-LYL1, pEF-BOS-E2A, pEF-BOS-TAL1 and pEF-BOS-HEB. The primer pairs used were as follows: LYL1, sense 5 0 -TCC ATGTGCCCGCCCCAGGCC-3 0 and antisense 5 0 -GGGTCA CCGCACCTCAGGACT-3 0 ; E47, sense 5 0 -TGGATGATGA ACCAGTCTCAG-3 0 antisense 5 0 -GGCTCACAGGTGCCC GGCTGG-3 0 ; SCL/TAL1, sense 5 0 -AGGATGACCGAGCG GCCGCCG-3 0 and antisense 5 0 -CCATCACCGAGGGCCGG CTCC-3 0 . To construct vectors expressing HEB, E2A or LYL1 fused with the VP16-activation domain (VAD), E47 and LYL1 cDNA fragments were subcloned into the EcoRI-SalI site and HEB cDNA fragment was cloned into the blunt BamHI site of the pVP16 vector (Clontech, Palo Alto, CA, USA), generating pVAD-HEB, pVAD-E2A and pVAD-LYL1. To construct vectors expressing E2A or HEB fused with the Gal4 DNAbinding domain (GBD), E47 cDNA fragment was subcloned into the EcoRI-SalI site and the HEB cDNA fragment was cloned into the blunt BamHI site of the pM vector (Clontech), producing pGBD-E2A and pGBD-HEB. The primer pairs used were as follows: LYL1, sense 5 0 -GATGAATTCTGCCC GCCCCAGGCC-3 0 and antisense 5 0 -GATGTCGACGGGT CACCGCACCTCAGGACT-3 0 ; E47, sense 5 0 -GATGAATT CAACCAGTCTCAGAGAATGGCA-3 0 and antisense 5 0 -GA TGTCGACGGCTCACAGGTGCCCGGCTGG-3 0 ; HEB, sense 5 0 -AATCCCCAGCAACAACGCATG-3 0 and antisense 5 0 -TTACATATGACCCATAGGGTT-3 0 . To generate pGL3-CD4-enh-pro, in which a firefly luciferase reporter cassette was driven by the CD4 enhancer-promoter, a CD4 proximal enhancer element and CD4 promoter were amplified from mouse spleen by PCR as described previously (Herblot et al.,  2000) . PCR products were sequentially subcloned into the pGL3-Basic vector (Promega, Madison, WI, USA) upstream of the firefly luciferase gene.
Generation of transgenic mice and genotyping
To generate LYL1 transgenic mice, mouse LYL1 cDNA was subcloned into the pEF-BOS expression vector at the XbaI site to yield pEF-BOS-LYL1, in which the LYL1 gene was under control of the EF-1a promoter. The 3 0 region of this construct contained a polyadenylation signal sequence from the human granulocyte colony-stimulating factor. pEF-BOS-LYL1 was digested with HindIII-PvuI to obtain a 2.7 kb-EF-1a-LYL1 fragment, which was purified with a commercial kit (GENE-CLEAN II Kit, Bio 101 system, QBIOgene, Albany, NY, USA) and microinjected into the pronuclei of fertilized oocytes derived from an F1 animal of DBAxC57BL/6. F1 mice were established by mating founder mice with C57BL/6 animals and were bred under specific pathogen-free condition. The animal experiment committee of the Graduate School of Medicine, Kyoto University approved these experiments. For genotyping, 10 mg of tail DNA was digested with PstI, separated on 1.0% agarose gel and transferred onto a Hybond-N membrane (Amersham Biosciences, Buckinghamshire, UK). Mouse LYL1 cDNA was labeled with a-32 P (Amersham) and used as a probe for Southern blot analysis and finally exposed to an X-ray film (Kodak, Rochester, NY, USA). Differentiation between homozygotes and heterozygotes was performed based on the density of the transgene.
Northern blot analysis
Total RNA was extracted from tissues with an ISOGEN reagent (NPGENE, Toyama, Japan). Ten micrograms of total RNA was denatured by glyoxal, electrophoresed on 1.5% agarose gel and transferred onto a Hybond-N membrane (Amersham). The blot was hybridized with a-32 P-labeled mouse LYL1 cDNA. The b-actin gene was used as an internal control. Bands were visualized by exposing the membrane to an X-ray film.
Antibodies
An anti-LYL1 rabbit polyclonal antibody was produced by a commercial supplier (Hokudo, Hokkaido, Japan). Briefly, 14-mer peptide (NH 3 -CPIKLEQTSLSPEVR-COOH) of the C-terminus of mouse LYL1 protein was synthesized and conjugated with keyhole limpet hemocyanin, which was used as an immunogen for JW rabbits. One week after the third immunization, whole serum was harvested and purified using a SulfoLink Kit (Pierce, Rockford, IL, USA). Anti-mouse CD4 (L3T4)-FITC, anti-mouse CD8a (Ly-2)-PE, anti-TCRab-FITC, anti-BP1-FITC, anti-B220-PE, anti-human E47 (G127-32) and anti-mouse CD45R/B220 (RA3-6B2) monoclonal antibodies were from BD Biosciences (San Jose, CA, USA). Anti-CD3-e polyclonal antibody (clone M-20, sc-1127) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunoprecipitation and western blot analysis Tissue proteins were prepared from thymus, liver, kidney and spleen by homogenizing in RIPA buffer (20 mM Tris, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 1% sodium deoxycholate, pH 7.4) supplemented with protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Mannheim, Germany). For each immunoprecipitation, 10 ml of polyclonal antibody against LYL1 was added to 400 mg of protein in a 100 ml-volume, incubated at 41C for 3 h, followed by addition of 50 ml of protein A Sepharose CL-4B (Amersham) and incubated for 1 h at 41C. After washing with 0.1 M LYL1 overexpression causes T-and B-cell lymphoma Y Zhong et al 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (pH 8.0), the pellets were resuspended in 50 ml electrophoresis sample buffer, followed by western blot analysis. Western blot analysis was performed as described previously (Toyokuni et al., 2003) .
X-ray photography and Alizarin red staining Mice were anesthetized with diethyl ether and X-ray photographs were taken (5 A, 30 kV and 20 s) by using SOFTEX CMB-2 machine (SOFTEX Company, Kanagawa, Japan). Mouse skeletons were stained for cartilage with Alcian blue and for bone with Alizarin red as described previously (Aplan et al., 1997) .
Histological analysis
Mice were killed by cervical dislocation. Tissue samples were fixed with 10% phosphate-buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin and observed under a light microscope. For immunohistochemistry, the avidin-biotin complex method was used as described previously (Toyokuni et al., 1997) .
Flow cytometric analysis
Tissues were homogenized and passed through a cell strainer (BD Falcon, Bedford, MA, USA) to generate a single-cell suspension. Cells (1 Â 10 6 ) were washed with phosphatebuffered saline (PBS) and incubated with 1:100 diluted antibodies against CD4 (L3T4), CD8a (Ly-2), TCRab, B220 or BP1 for 20 min on ice. Then, the cells were analysed using a FACS (Becton Dickinson, Franklin Lakes, NJ, USA) after washing with PBS.
TCR and IgH rearrangement analysis
Genomic DNA was extracted using a Puregene Tissue DNA Isolation Kit (Gentra, Minneapolis, MN, USA). Analyses on the TCR-b gene and IgH gene rearrangement were performed as described (van Dongen and Wolvers-Tettero, 1991; Larson et al., 1995) . Briefly, for TCR-b rearrangement analysis, 10 mg of DNA from thymus, spleen and liver was digested with either HindIII or PvuII, transferred onto a Hybond-N membrane (Amersham) and hybridized with a-32 P-labeled probe. The HindIII filter was hybridized with a J-b2 probe (Malissen et al., 1984) to obtain a spectrum of TCR-b gene rearrangement, and the obtained rearrangements were further confirmed by hybridizing the PvuII filter with a J-b1 probe (Malissen et al., 1984) . For IgH rearrangement analysis, genomic DNA isolated from spleen, liver and lymph node was digested with BglII and hybridized with a-32 P-labeled J H probe (Sakano et al., 1980) . The rearranged IgH gene bands detected in the BglII filters were further confirmed by using Sac I digestion. Signals were detected by exposure to an X-ray film.
Cell culture 293T cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (GIBCO, Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mmol/l L-glutamine at 371C and 5% CO 2 .
Mammalian two-hybrid assay Mammalian two-hybrid assay was performed using a Mammalian Matchmaker Two-Hybrid Assay Kit (Clontech) following the protocol supplied by the manufacturer. The following vectors were used in this assay. The VAD-expression vectors used were pVAD-HEB, pVAD-E2A and pVAD-LYL1 and GBD-expression vectors used were pGBD-E2A and pGBD-LYL1. pG5CAT (Clontech) was used as a reporter in which the chloramphenicol acetyltransferase (CAT) gene was driven by a minimal E1b promoter connected to five GAL4 binding sites. GBD and VAD cloning vector (Clontech) were used as basal control for basic expression level of CAT. pM3-VP16 (Clontech) encodes a fusion of the GBD and VAD and was used as a positive control. The VAD expression vector, GBD expression vector and pG5CAT vector were cotransfected into 293T cells using Lipofectamine 2000 reagent (Invitrogen Life Technologies) according to the manufacturer's protocol. The total amount of transfected DNA was adjusted by adding pEF-BOS-empty vector. Forty-eight hours after transfection, cells were harvested and tested for CAT activity using a CAT ELISA Kit (Roche Diagnostics, Indianapolis, IN, USA). Triplicate experiments were done for each transfection.
Luciferase assay pEF-BOS-LYL1, pEF-BOS-E2A, pEF-BOS-SCL/TAL1 and pEF-BOS-HEB were used. pGL3-CD4-enh-pro (CD4-enhpro) was used as a reporter, in which a firefly luciferase reporter gene was driven by a CD4 enhancer-promoter. A pGL3-Basic vector (Promega) was used as a negative control in which the firefly luciferase gene lacked an enhancer or promoter element. Vector pRL-TK (Promega) expressing sea pansy luciferase was used as a control. Expression vectors in various combinations were co-transfected with luciferase reporter vectors into 293T cells using Lipofectamine 2000 reagent (Invitrogen Life Technologies). The pEF-BOS-empty vector was used to adjust the total amount of transfected DNA. The luciferase assay was performed 48 h after transfection using the Dual-Luciferase-Reporter Assay System (Promega). Luciferase activity was determined with the Genelight 55 luminometer (Microtec, Chiba, Japan). Firefly luciferase activities were normalized by sea pansy luciferase activities. Each transfection experiment was carried out in triplicate.
Semiquantitative reverse transcriptase (RT)-PCR
Total RNA was extracted from tissue samples using ISOGEN reagent (NPGENE, Toyama, Japan). RNA was treated with DNase I (Invitrogen Life Technologies) to digest remnant genomic DNA. cDNA was synthesized from 3 mg of total RNA by the SuperScript Preamplification System (Invitrogen Life Technologies) according to the protocol recommended by the manufacturer. PCR was initially performed with different cycle numbers to find the optimal number for quantitative amplification of the target products. Primers for studying gene expression were 5 0 -CACAGAGTAGAGGCTGCACGC-3 0 (sense, GenBank NM_008535; 1186-1206) and 5 0 -CAGGTGG GGACCCTCACTCTA-3 0 (antisense, in the pEF-BOS vector) for LYL1 (GenBank NM_008535; annealing temperature, 601c; cycles, 30); 5 0 -GTGGCAGATGGCAGCCTGCACC-3 0 (sense) and 5 0 -GGAGTAGATCGAGGCCAGTGC-3 0 (antisense) for E2A (GenBank AF352579; 735-2003; annealing temperature, 621C; cycles, 28); 5 0 -CTTGTACTCCTGGTG GTGCTG-3 0 (sense) and 5 0 -CAGAGCTGGATAAGCAGAC AG-3 0 (antisense) for CD5 (GenBank NM_007650; 1284-1529; annealing temperature, 601C; cycles, 28); 5 0 -CTGACAAAGA AGAAGGTGGAG-3 0 (sense) and 5 0 -CATGTCCATCAAAG CAGACAC-3 0 (antisense) for RAG1 (GenBank NM_009019; 1350-1804; annealing temperature, 581C; cycles, 28); 5 0 -GGA ATAGTGTAGCTGACTGCC-3 0 (sense) and 5 0 -CACTGGA GACAGAGATTCCTC-3 0 (antisense) for RAG2 (Genbank NM_009020; 727-993; annealing temperature, 581C; cycles, 27); 5 0 -CACTGCTGGTAGATGGAAGGC-3 0 (sense) and 5 0 -CTCCTGGCTGTCGAAGATTCC-3 0 (antisense) for pTa 
